Greenway Reports First Quarter Fiscal 2027 Financial Results

Greenway Greenhouse Cannabis reported Q1 FY2027 net revenue of $2.23M (+38% YoY) and record sales volume of 2.33M grams (~8% above its prior quarterly record). Despite a lower average net sales price driving gross margin to 12%, the company generated positive Adjusted EBITDA of $47.9k and $36.8k cash from operating activities (vs cash used of $865.5k in Q1 FY2026). Management attributed weaker pricing/margins to legacy inventory sales tied to product-mix transitions, while citing a 30% reduction in cash cost per gram sold to $0.69 and positioning for stronger, more consistent future performance.

Analysis

This print is more useful as a proof-of-process than as a valuation inflection. The only durable signal is that a low-cost greenhouse model can generate positive operating cash in a commodity-like category, which supports a tighter spread between the best operators and the cash-burning tail in Canadian cannabis. That said, the economics still look fragile: margin recovery appears to depend on mix normalization, not pricing power, so any demand weakness or channel destocking would quickly wipe out the current operating leverage.

The bigger second-order issue is financing optionality. For a microcap in a capital-intensive sector, even modest positive cash flow can reduce near-term dilution risk and improve counterparties’ willingness to sign supply agreements, but the absolute cash balance remains too small to treat this as self-funding. The consultant-share issuance also matters: it signals equity is still being used as currency, which tends to cap multiple expansion until the market sees several quarters where cash generation is not flattered by working-capital timing or inventory accounting.

Contrarian view: the market may focus on EBITDA breakeven and miss that true earnings are still burdened by financing costs, so the stock can rerate on sentiment more than fundamentals in the next 1-3 months. The thesis is falsified if the next quarter shows operating cash reversal, further ASP compression, or another equity-funded expense program. Over 6-18 months, the upside case only works if international medical shipments become recurring enough to reduce dependence on legacy inventory liquidation.

Key Decisions for Investors

• Do not initiate a fresh long in GWYT on this release; wait for 2 consecutive quarters of positive operating cash flow and stable gross margin before underwriting any rerating.
• If already exposed to Canadian cannabis, use GWYT as a relative-quality watch item versus higher-burn peers like TLRY, OGI, or CGC; prefer companies with stronger cash buffers over those merely showing EBITDA optics.
• Set a catalyst alert for the next quarterly filing: if cash from operations turns negative again or gross margin stays near the low-teens, treat the current optimism as a fade and avoid buying weakness.
• For event-driven desks only: small speculative long could be considered on a pullback if management can show export/customer diversification and improving average selling price, but position size should reflect microcap liquidity and dilution risk.